BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20969960)

  • 1. Mitogen-activated protein kinases in hepatocellular carcinoma development.
    Min L; He B; Hui L
    Semin Cancer Biol; 2011 Feb; 21(1):10-20. PubMed ID: 20969960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.
    Ito Y; Sasaki Y; Horimoto M; Wada S; Tanaka Y; Kasahara A; Ueki T; Hirano T; Yamamoto H; Fujimoto J; Okamoto E; Hayashi N; Hori M
    Hepatology; 1998 Apr; 27(4):951-8. PubMed ID: 9537433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development.
    Wang J; Tai G
    Target Oncol; 2016 Dec; 11(6):723-738. PubMed ID: 27392951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of MAP kinases and their cross-talk in TGF-beta1-induced apoptosis in FaO rat hepatoma cell line.
    Park HJ; Kim BC; Kim SJ; Choi KS
    Hepatology; 2002 Jun; 35(6):1360-71. PubMed ID: 12029621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells.
    Stone AA; Chambers TC
    Exp Cell Res; 2000 Jan; 254(1):110-9. PubMed ID: 10623471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.
    McKillop IH; Schmidt CM; Cahill PA; Sitzmann JV
    Hepatology; 1997 Dec; 26(6):1484-91. PubMed ID: 9397988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of MAPKs in adipocyte differentiation and obesity.
    Bost F; Aouadi M; Caron L; Binétruy B
    Biochimie; 2005 Jan; 87(1):51-6. PubMed ID: 15733737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma].
    Zhu H; Chen XP; Luo SF; Guan J; Zhang WG; Zhang BX; Mao CP
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(13):917-20. PubMed ID: 17953842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
    Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
    Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma.
    Wang SN; Lee KT; Tsai CJ; Chen YJ; Yeh YT
    Eur J Clin Invest; 2012 Dec; 42(12):1295-301. PubMed ID: 23033928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of mitogen-activated protein kinase pathways during Escherichia coli-induced apoptosis in U937 cells.
    Wang JH; Zhou YJ; He P; Chen BY
    Apoptosis; 2007 Feb; 12(2):375-85. PubMed ID: 17191113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-activated protein kinases (p38 and c-Jun NH2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophy.
    Sopontammarak S; Aliharoob A; Ocampo C; Arcilla RA; Gupta MP; Gupta M
    Cell Biochem Biophys; 2005; 43(1):61-76. PubMed ID: 16043884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of mitogen-activated protein kinase and its upstream regulated signal in human hepatocellular carcinoma].
    Zhu J; Leng X; Dong N; Liu Y; Li G; Du R
    Zhonghua Wai Ke Za Zhi; 2002 Jan; 40(1):1-16. PubMed ID: 11955369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.
    Johnson GL; Lapadat R
    Science; 2002 Dec; 298(5600):1911-2. PubMed ID: 12471242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.